HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luis Paz-Ares Selected Research

necitumumab

3/2019Necitumumab for the treatment of advanced non-small-cell lung cancer.
1/2018Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
1/2018EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.
1/2018Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.
2/2016Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?
7/2015Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
3/2015Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Luis Paz-Ares Research Topics

Disease

105Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 12/2004
95Neoplasms (Cancer)
06/2022 - 05/2002
38Lung Neoplasms (Lung Cancer)
06/2022 - 06/2007
38Disease Progression
01/2022 - 04/2005
17Neutropenia
01/2022 - 05/2002
14Neoplasm Metastasis (Metastasis)
01/2022 - 08/2002
13Carcinoma (Carcinomatosis)
12/2020 - 08/2002
12Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2022 - 06/2007
11Adenocarcinoma
01/2022 - 05/2013
11Exanthema (Rash)
01/2017 - 12/2004
10Adenocarcinoma of Lung
03/2021 - 06/2014
7Febrile Neutropenia
01/2021 - 06/2004
7Fatigue
11/2020 - 03/2012
6Body Weight (Weight, Body)
01/2022 - 07/2015
6Colorectal Neoplasms (Colorectal Cancer)
03/2015 - 05/2007
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 05/2013
5Thrombocytopenia (Thrombopenia)
01/2021 - 04/2012
5Nausea
01/2019 - 01/2014
4Asthenia
01/2021 - 01/2008
4Pneumonia (Pneumonitis)
01/2021 - 11/2017
4Carcinogenesis
03/2020 - 01/2015
4Sarcoma (Soft Tissue Sarcoma)
01/2020 - 04/2012
4Breast Neoplasms (Breast Cancer)
12/2019 - 08/2013
3Brain Neoplasms (Brain Tumor)
06/2022 - 01/2017
3Interstitial Lung Diseases (Interstitial Lung Disease)
01/2022 - 01/2019
3Chest Pain (Chest Pains)
10/2021 - 01/2020
3Dyspnea (Shortness of Breath)
10/2021 - 01/2020
3Cough
10/2021 - 01/2020
3Fever (Fevers)
12/2019 - 05/2002
3Stomatitis
01/2019 - 11/2014
3Vomiting
01/2017 - 01/2014
3Chronic Obstructive Pulmonary Disease (COPD)
12/2016 - 02/2013
3Acne Vulgaris
01/2016 - 01/2011
3Diarrhea
12/2015 - 01/2008
3Pathologic Processes
09/2014 - 01/2012
2Melanoma (Melanoma, Malignant)
01/2022 - 03/2009
2Hepatitis
01/2021 - 01/2019
2Sepsis (Septicemia)
01/2021 - 07/2011
2Respiratory Insufficiency (Respiratory Failure)
01/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

37Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2011
31PlatinumIBA
06/2022 - 01/2005
23ErbB Receptors (EGF Receptor)IBA
06/2022 - 06/2007
23Cisplatin (Platino)FDA LinkGeneric
01/2021 - 08/2002
19Proteins (Proteins, Gene)FDA Link
03/2021 - 06/2010
16Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2021 - 06/2007
16Tyrosine Kinase InhibitorsIBA
10/2021 - 01/2008
14Pharmaceutical PreparationsIBA
06/2022 - 12/2002
14Carboplatin (JM8)FDA LinkGeneric
01/2021 - 12/2004
12NivolumabIBA
01/2021 - 07/2015
12Pemetrexed (MTA)FDA Link
01/2020 - 12/2002
11durvalumabIBA
06/2022 - 11/2017
11pembrolizumabIBA
01/2022 - 11/2018
10B7-H1 AntigenIBA
11/2021 - 08/2017
9Messenger RNA (mRNA)IBA
03/2020 - 07/2007
8Paclitaxel (Taxol)FDA LinkGeneric
06/2021 - 08/2002
7LigandsIBA
01/2022 - 10/2015
7AfatinibIBA
01/2022 - 01/2016
7RamucirumabIBA
10/2021 - 01/2017
7Docetaxel (Taxotere)FDA Link
04/2019 - 07/2007
7necitumumabIBA
03/2019 - 03/2015
7GemcitabineFDA Link
01/2017 - 08/2002
6Etoposide (VP 16)FDA LinkGeneric
06/2022 - 11/2017
6Immune Checkpoint InhibitorsIBA
01/2021 - 06/2015
6Phosphotransferases (Kinase)IBA
08/2020 - 06/2010
6Alanine Transaminase (SGPT)IBA
01/2020 - 05/2007
6Gefitinib (Iressa)FDA Link
01/2020 - 09/2009
6MicroRNAs (MicroRNA)IBA
01/2018 - 01/2012
5Monoclonal AntibodiesIBA
06/2022 - 08/2017
5Biological ProductsIBA
01/2022 - 01/2012
5PM 01183IBA
06/2021 - 01/2017
5Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
08/2020 - 06/2010
4Cetuximab (Erbitux)FDA Link
06/2022 - 01/2011
4Irinotecan (Camptosar)FDA LinkGeneric
01/2022 - 05/2005
4CytokinesIBA
03/2021 - 01/2016
4IpilimumabIBA
01/2021 - 05/2018
4Transaminases (Aminotransferases)IBA
01/2019 - 05/2007
3Cadherins (E-Cadherin)IBA
03/2021 - 01/2018
3EnzymesIBA
03/2021 - 01/2016
3AntibodiesIBA
01/2020 - 01/2014
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2020 - 05/2007
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2019 - 04/2013
3Anaplastic Lymphoma KinaseIBA
01/2019 - 05/2012
3DNA (Deoxyribonucleic Acid)IBA
01/2019 - 05/2015
3TrabectedinIBA
09/2012 - 05/2007
3Fluorouracil (Carac)FDA LinkGeneric
01/2008 - 05/2005
210-N-nonylacridinium orange (NAO)IBA
06/2022 - 01/2018
2Doxorubicin (Adriamycin)FDA LinkGeneric
06/2021 - 01/2019
2ImmunosorbentsIBA
03/2021 - 12/2016
2geldanamycinIBA
03/2021 - 01/2019
2Heat-Shock Proteins (Heat-Shock Protein)IBA
03/2021 - 01/2019
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
03/2020 - 12/2019

Therapy/Procedure

60Drug Therapy (Chemotherapy)
01/2022 - 05/2002
56Therapeutics
06/2022 - 07/2007
9Immunotherapy
03/2022 - 07/2015
6Chemoradiotherapy
01/2022 - 12/2005
5Radiotherapy
06/2022 - 06/2007
3Aftercare (After-Treatment)
01/2020 - 10/2016
3TP protocol
04/2012 - 08/2002
2Intravenous Administration
06/2022 - 01/2017
2Precision Medicine
07/2020 - 01/2017